Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q1 2017 Earnings Presentation

9 slides from Lumos Pharma's earnings presentation, May 4, 2017

  1. Slide 1: First Quarter 2017 Results

    NewLink Genetics Corporation Nasdaq: NLNK May 4, 2017 First Quarter 2017 Results

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments  Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates / Guidance on Timing of Data  Nicholas N. Vahanian, M.D., President & CMO First Quarter 2017 Financial Results  Mr. Henneman

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w

  4. Slide 4: Q1 Takeaways

    Q1 Takeaways  Emerging clinical data are validating the IDO pathway as central to immunosuppression  IDO pathway inhibition has the potential to enhance patient outcomes when used in combination with other cancer therapies  NewLink has two distinct types of IDO pathway inhibitors in the clinic –

  5. Slide 5: Best Response by Patient: Non-ocular Versus Ocular

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Best Response by Patient 5 Distinct Difference in Non-ocular Versus Ocular Patients 80% 100% 40% 60% 0% 20% –40% –20% –60% –80% –100%

  6. Slide 6: Change in Tumor Volume Over Time: Durable and Ongoing Responses

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Change in Tumor Volume Over Time 6 Durable and Ongoing Responses PR, partial response. Note: 1 patient was unevaluable for response d

  7. Slide 7: Anticipated Highlights for 2017 Clinical Programs

    Anticipated Highlights for 2017 Clinical Programs  Metastatic castration resistant prostate cancer: – Abstract 3066: Randomized placebo-controlled Phase 2 clinical trial data to be presented at ASCO on Monday, June 5, 2017, 9:00 AM ET-12:30 PT ET  Metastatic pancreatic cancer: – Indoximod in combi

  8. Slide 8: First Quarter 2017 Financial Results

    First Quarter 2017 Financial Results Cash and Equivalents $118.2 million Debt ~$0.5 million YE 2017 Cash (Projected) ~$75 million Quarterly Negative Cash-Flow ~$13 million Shares Outstanding 29.2 million Market Capitalization ~$500 million Headcount 127 8 Major 2017 YE Cash Projection Assumptions: T

  9. Slide 9: Q & A

    9 Q & A

NewLink Genetics — Q1 2017 Earnings Presentation on 6ix